PDCD1 and metastatic melanoma: This promising therapeutic candidate is now undergoing rigorous evaluation in a Phase I/II clinical trial (NCT04618393), which aims to assess its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors, including locally advanced/metastatic melanoma with >1 prior therapy (PD-1/L1 +/− CTLA-4 ICI).